Switch theme
Sign up to access all valuation multiples
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
1991
580
LTM Revenue $483M
LTM EBITDA $16.0M
$2.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
BioCryst Pharma has a last 12-month revenue of $483M and a last 12-month EBITDA of $16.0M.
In the most recent fiscal year, BioCryst Pharma achieved revenue of $451M and an EBITDA of $12.8M.
BioCryst Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See BioCryst Pharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $331M | $451M | XXX | XXX | XXX |
| Gross Profit | $264M | $327M | XXX | XXX | XXX |
| Gross Margin | 80% | 72% | XXX | XXX | XXX |
| EBITDA | -$116M | $12.8M | XXX | XXX | XXX |
| EBITDA Margin | -35% | 3% | XXX | XXX | XXX |
| Net Profit | -$247M | -$227M | XXX | XXX | XXX |
| Net Margin | -75% | -50% | XXX | XXX | XXX |
| Net Debt | $429M | $701M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, BioCryst Pharma's stock price is $7.
BioCryst Pharma has current market cap of $1.5B, and EV of $2.0B.
See BioCryst Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.0B | $1.5B | XXX | XXX | XXX | XXX | $-0.33 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, BioCryst Pharma has market cap of $1.5B and EV of $2.0B.
BioCryst Pharma's trades at 4.1x LTM EV/Revenue multiple, and 122.5x LTM EBITDA.
Analysts estimate BioCryst Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for BioCryst Pharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.0B | XXX | XXX | XXX |
| EV/Revenue | 4.3x | XXX | XXX | XXX |
| EV/EBITDA | 152.9x | XXX | XXX | XXX |
| P/E | -16.6x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -36.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpBioCryst Pharma's NTM/LTM revenue growth is 21%
BioCryst Pharma's revenue per employee for the last fiscal year averaged $0.8M, while opex per employee averaged $0.8M for the same period.
Over next 12 months, BioCryst Pharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate BioCryst Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for BioCryst Pharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 36% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 3% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -111% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 24% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.8M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.8M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 39% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 98% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BioCryst Pharma acquired XXX companies to date.
Last acquisition by BioCryst Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . BioCryst Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was BioCryst Pharma founded? | BioCryst Pharma was founded in 1991. |
| Where is BioCryst Pharma headquartered? | BioCryst Pharma is headquartered in United States of America. |
| How many employees does BioCryst Pharma have? | As of today, BioCryst Pharma has 580 employees. |
| Who is the CEO of BioCryst Pharma? | BioCryst Pharma's CEO is Mr. Jon P. Stonehouse. |
| Is BioCryst Pharma publicy listed? | Yes, BioCryst Pharma is a public company listed on NAS. |
| What is the stock symbol of BioCryst Pharma? | BioCryst Pharma trades under BCRX ticker. |
| When did BioCryst Pharma go public? | BioCryst Pharma went public in 1994. |
| Who are competitors of BioCryst Pharma? | Similar companies to BioCryst Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of BioCryst Pharma? | BioCryst Pharma's current market cap is $1.5B |
| What is the current revenue of BioCryst Pharma? | BioCryst Pharma's last 12-month revenue is $483M. |
| What is the current EBITDA of BioCryst Pharma? | BioCryst Pharma's last 12-month EBITDA is $16.0M. |
| What is the current EV/Revenue multiple of BioCryst Pharma? | Current revenue multiple of BioCryst Pharma is 4.1x. |
| What is the current EV/EBITDA multiple of BioCryst Pharma? | Current EBITDA multiple of BioCryst Pharma is 122.5x. |
| What is the current revenue growth of BioCryst Pharma? | BioCryst Pharma revenue growth between 2023 and 2024 was 36%. |
| Is BioCryst Pharma profitable? | Yes, BioCryst Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
